

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 August 2023 (24.08.2023)



(10) International Publication Number
WO 2023/159001 A1

- (51) **International Patent Classification:**
G01N 33/50 (2006.01) *G01N 33/574* (2006.01)
- (21) **International Application Number:**
PCT/US2023/062551
- (22) **International Filing Date:**
14 February 2023 (14.02.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/310,438 15 February 2022 (15.02.2022) US
- (71) **Applicant: KITE PHARMA, INC.** [US/US]; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).
- (72) **Inventors: ADHIKARY, Sabina;** Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **BOT, Adrian, I.;** 3090 Franklin Canyon Drive, Beverly Hills, CA 90210 (US). **CHOU, Szu-Ting;** 423 Amaz Drive, Apartment 202, Los Angeles, CA 90048 (US). **SONG, Qinghua;** Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

SPETH, Kelly; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **TIWARI, Gayatri, R.;** Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).


(74) **Agent: LOPEZ, Miguel, A.** et al.; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) **Title:** PREDICTING ADVERSE EVENTS FROM IMMUNOTHERAPY

FIG. 3



(57) **Abstract:** The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non- T cells, TCR-based therapies, CAR-based therapies, bispecific T-cell engagers (BiTEs), and/or immune checkpoint blockade).

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*